MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? by Walter, W et al.
Most of the tumour antigens defined by murine or human T cells
represent targets for major histocompatibility complex (MHC)
class I restricted CD8+ T cells. Nevertheless, recent data
(reviewed in Pardoll and Topalian, 1998) rekindled interest in
CD4+ T cells mediating anti-tumour-directed immune responses.
Both, CD4 and CD8 T cell epitopes may have to be incorporated
in a tumour vaccine in order to induce a strong and effective
cellular immune response. Tumour-specific T cells may directly
recognize MHC class II-positive tumour cells (Mongini et al,
1996; Armstrong et al, 1997), or they may confer protective immu-
nity on cancer cells in the absence of MHC class II molecules
(Ossendorp et al, 1998). Thus, efficient MHC class II restricted
presentation of tumour-associated antigens, either by tumour cells
themselves, or alternatively by professional antigen-presenting
cells, appears instrumental in initiating CD4+ T cell responses.
Major histocompatibility complex (MHC) class II molecules are
heterodimeric (αβ ) cell surface glycoproteins which present
peptides derived from self or foreign antigens to CD4+ T cells.
Newly synthesized MHC class II α and β chains assemble in the
endoplasmic reticulum (ER) with a third glycoprotein, the
invariant chain (Ii), to nonameric (αβ -Ii)3 complexes (Cresswell,
1996). These nonamers are targeted by signals within the cyto-
plasmic domain of the Ii (Bakke and Dobberstein, 1990) to
specialized compartments of the endocytic pathway termed MIICs
(MHC class II compartments), where peptide loading occurs
(Kleijmeer et al, 1997). During transport, Ii is stepwise proteolyti-
cally cleaved (Cresswell, 1998) yielding a nested set of Ii derived
peptides, termed CLIP, for MHC class II-associated invariant
peptides, which occupy the peptide-binding groove of class II αβ
dimers (Riberdy et al, 1992). CLIP is subsequently exchanged
for tightly bound antigenic peptides derived from internalized
antigens or endogenous proteins (Wolf and Ploegh, 1995).
Although exchange of CLIP for antigenic peptides might occur
spontaneously in MHCIIs at lysosomal-like pH (Urban et al,
1994), H2-M/DM is required for that final step of peptide loading
by many MHC class II alleles (Denzin et al, 1994; Miyazaki et al,
1996; Wolf et al, 1998). H2-M/DM has been shown to interact
with MHC class II in MIICs (Sanderson et al, 1996) and to
catalyze the exchange of CLIP for cognate peptides by facilitating
the removal of CLIP and stabilizing the transiently peptide-free
state of MHC class II molecules following CLIP release (Denzin
et al, 1996). Simultaneously, H2M/DM functions as a peptide
editor, which serves to positively select peptides that can stably
bind to MHC class II molecules (Van Ham et al, 1996). Thus,
expression of H2-M/DM molecules may critically affect the
peptide repertoire displayed to the T cell compartment. In contrast
to the HLA-DM loci in humans, the murine H2-M region encoded
within the MHC contains one Ma gene, but two Mb genes, termed
Mb1 and Mb2 (Cho et al, 1991; Kelly et al, 1991). Regulation of
MHC class II genes occurs primarily at the transcriptional level
(Mach et al, 1996) and is controlled by a non-DNA-binding
cofactor, the class II trans-activator CIITA (Mach et al, 1996).
Until this end, the potential role of a differential Mb1 or Mb2
expression in professional or non-professional APCs (i.e. tumour
cells) has not been addressed.
Here, we investigated the regulation of H2-M, MHC class II and
CIITA gene expression in murine tumour cells lines by Th1 (IFN-
γ )- and Th2 (IL-4 or IL-10) cytokines. In addition, we examined
whether Mb1 and Mb2, and by consequence Mαβ 1 and Mαβ 2
heterodimers, are differentially expressed in different tumour
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antigens to MHC class II-restricted T cell lines.
MATERIALS AND METHODS
Animals
C57BL/6 mice (H2b) and New Zealand White rabbits were
purchased from Charles River Laboratories (Sulzfeld, Germany).
TCR DO11.10 transgenic mice expressing a TCR-α /β specific for
peptides 323–339 from ovalbumin presented by H2-Ad (Murphy 
et al, 1990) and mice expressing a TCR-α /β specific for peptides
111–119 from influenza haemagglutinin (HA) presented by H2-Ed
(Kirberg et al, 1994) were generous gifts from Dr D Loh and 
Dr J Kirberg at the Basel Institute for Immunology (Basel,
Switzerland).
Cell lines and culture conditions
Murine cell lines included: Renca (H2d) renal adenocarcinoma
kindly provided by Dr B Seliger (University of Mainz, Germany),
P815 (H2d) mastocytoma, TS/A (H2d) mammary adenocarcinoma,
MC-38 (H2b) colon adenocarcinoma, MCA-102 (H2b) fibrosar-
coma, L929 (H2b) fibroblasts, B16 (H2b) melanoma, RMA (H2b)
T cell lymphoma, RMAs (H2b) T cell lymphoma, EL-4
(H2b) thymoma, YAC-1 (H2a) T cell leukaemia, P388D1 (H2d)
macrophages, IC-21 (H2b) macrophages, A20 (H2d) B cell
lymphoma (kindly provided by Dr G Hämmerling, DKFZ,
Heidelberg, Germany) and LB27.4 (H2d) B cell lymphoma. Cell
lines were maintained in RPMI-1640 (Gibco, Eggenstein,
Germany) supplemented with 10% heat-inactivated fetal bovine
serum, 2 mM L-glutamate, 100 IU ml–1 penicillin, 100 µ g ml–1
streptomycin (all from Gibco) and 50 µ M 2-mercaptoethanol
(Sigma, Deisenhofen, Germany), termed complete medium (CM).
In experiments using rIL-4 (a generous gift from Shering Ploegh,
Kenilworth NJ, USA) rIL-10 or rIFN-γ (both from PharMingen,
Hamburg, Germany), culture medium was changed before experi-
ment and IL-4 (250 U ml–1), IL-10 (100 ng ml–1) or IFN-γ
(150 U ml–1) were added for 72 h.
Preparation of CD4+ T cells
Isolation of CD4+ Mel-14high naive T cells from spleens of TCR
transgenic mice and generation of CD4+ Th cells that express a
Th1 cytokine pattern after specific activation with antigen, were
performed as recently described in detail elsewhere (Lingnau et al,
1998).
Antibodies
The anti-class II mAbs FITC-conjugated 39–10–8 (anti-H2-Ad)
and PE-conjugated 14–4–4S (anti-H2-Ek,d) were obtained from
PharMingen; FITC-conjugated secondary staining reagents: goat
anti-hamster IgG, rabbit anti-rat IgG, goat antimouse IgG and
goat anti-rabbit IgG were purchased from Dianova (Hamburg,
Germany) and unlabelled, FITC- or PE-conjugated isotype-
matched control antibodies were from Coulter-Immunotech
(Hamburg, Germany). The rabbit antisera R.Mα -C.69.3, R.M-
β 1/2–C.71.3 and R.hCLIP73.11 were prepared by immunizing
rabbits with carboxy-terminal peptides from H2-Mα (aa
238–248) or H2-Mβ 1/2 (aa 228–243) coupled by an added amino
terminal cysteine to diphtheria toxoid-MCS (Chiron Mimotopes,
Victoria, Australia). Antisera were affinity purified using columns
of NHS-activated Fast Flow Sepharose 4 (Pharmacia, Freiburg,
Germany) cross-linked to the respective Mα , Mβ or CLIP peptide
according to the manufacturer’s instructions. Individual fractions
of affinity purified antisera were screened for specific antibody
titres by ELISA and Western blot analysis using T2 cell lines
transfected either with Ma,  Mb1 or  Mb2 genes (Walter et al,
in press).
Template cDNA preparation and competitive reverse
transcription PCR
Total RNA isolation and cDNA synthesis have been previously
described (Walter et al, 1996). Briefly, PCR amplification was
performed in an amplification mix adjusted to 50 µ l containing
50–100 ng cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 
1.5 mM MgCl2, 0.01 (w/v) gelatin, 1 mM each dNTP, 25 pmol
each primer and 2.5 U of Ampli Taq Gold Polymerase (Perkin-
Elmer, Weiterstadt, Germany). The RT-PCR amplification profile
involved an initial denaturation step at 94° C for 10 min followed
by 35 cycles of 94° C for 1 min, 62° C for 1 min and 72° C for 
1 min; the last extension was for 10 min at 72° C. The following
primers were used for PCR: β -actin sense 5′ -TGGAATCCT-
GTGGCATCCATGAAAC-3′ ;  β -actin antisense 5′ -TAAAAC
GCAGCTCAGTAACAGTCCG-3′ ; Ma sense 5′ -AAGGTATG-
GAGCATGAGCAGAAGT-3′ ; Ma antisense 5′ -GATCAGTCAC-
CTGAGCACGGT-3′ ; two sets of primers were used to amplify
CIITA: sense 5′ -CCATCTTGCGCCCGCAGGCT-3′ ; antisense 5′ -
GTGCCAGGCTCTTGGCTCC-3′ ; and a set previously identified
to amplify both human and mouse CIITA (Chang et al, 1996).
Competitive RT-PCR analysis has been performed as previously
described (Bouaboula et al, 1992). After reverse transcription,
cDNA concentrations were normalized by co-amplifying constant
amounts of cDNA (50 ng) and known concentrations of the seri-
ally diluted β actin competitor plasmid pMCQ (kindly provided by
Dr Blankenstein, University of Berlin, Germany). PCR products
generated by the competitor plasmid pMCQ (248 bp) and the
endogenous β -actin mRNA (348 bp) were resolved on ethidium-
bromide-stained agarose gels and band intensities were quantified
as OD302 units by means of the Gelprint 2000i densitometer (MWG
Biotech, Ebersberg, Germany). The pMCQ concentration which
was required to achieve equal band intensities for both fragments
was determined by linear regression analysis and the number of
copies of β -actin mRNA molecules per µ g of total RNA for each
cDNA sample calculated (Bouaboula et al, 1992). For semiquanti-
tative analysis of Ma mRNA expression, a heterologous Ma
competitor fragment (termed Ma cf) was generated as described
according to MIMIC PCR technology (Haberhausen et al, 1998).
Following co-amplification, Ma cf yields a 742 bp fragment as
compared to the 794 bp PCR product derived from endogenous
Ma mRNA. Equivalent to β -actin mRNA analysis, the number of
copies of Ma mRNA molecules per µ g of total RNA were deter-
mined for each sample by titration of known amounts of the seri-
ally diluted Ma cf against constant amounts of cDNA 
(100 ng). In order to compare differences in Ma mRNA expression
levels, samples of each cell line were normalized for cDNA
contents based on the number of β -actin mRNA molecules.
Expression of Ma transcripts in cytokine-treated samples of each
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cytokine-treated cells/Ma mRNA expression (= 1) in non-treated
cells.
Ratio reverse transcriptase PCR analysis
The ratio reverse transcriptase PCR (ratio-RT-PCR) assay
performed in this study was based on the simultaneous amplifica-
tion of Mb1 and  Mb2 transcripts using primers (Mb1/2 sense 
5′ -GGACCATGGCTGCACTCTGGC-3′ , Mb1/2 antisense 5′ -
GCATCACGGGCTCCCTTGTGT-3′ ) annealing within conserved
regions (exon 1 and 3) of both Mb messages (Walter et al, 1996).
Equal amplification efficiency of both Mb transcripts was assured
by comparative cycle kinetic and linear regression analyses
(Bouaboula et al, 1992) using cloned Mb1 and Mb2 full-length
cDNA (Walter et al, 1996). Discrimination between co-amplified
Mb transcripts was performed utilizing Mb1- and Mb2-specific
restriction sites within exon 2. Based on the polymorphism of Mb1
and Mb2 genes (Walter et al, 1996), we took advantage of the
restriction enzymes EaeI and XbaI for discrimination of Mb1d and
Mb2d transcripts, respectively. BamHI, which cleaves at different
sites within both Mba,b targets, was implemented to discriminate
between Mb1a,b and Mb2a,b messages. PCR was performed using
Ampli Taq Gold Polymerase and standard PCR conditions. After
25 cycles, the amplified mixture was diluted 25-fold in fresh
PCR amplification mixture containing 25 nCi µ l–1 [α -32P]dCTP
(ICN, Eschwege, Germany) and then two additional cycles were
performed. The labelled Mb PCR products, or their respective
restriction fragments, were separated on 6% polyacrylamide gels.
For quantification of individual Mb fragments, gels were subjected
to autoradiography. Corresponding bands were excised from the
gel and radioactivity was measured by means of a β -counter
(LS6000TA, Beckman, München, Germany) using a Cerenkov
program. In order to calculate the ratio of Mb1 and Mb2 expres-
sion levels, their respective restriction fragments were corrected
for length and cytosine and guanine (GC) content, since exclu-
sively dCTP was radioactively labelled in the assay.
Western blot analysis
Cells were lysed at 1 × 107 cells ml–1 in 20 mM Tris-HCl (pH 7.4)
buffer containing 1% NP40 (Sigma), 5 mM MgCl2, 5 µ g ml–1
chymostatin, 2.5 µ g ml–1 leupeptin, 5 µ g ml–1 pepstatin A, 200 µ M
PMSF (all protease inhibitors were from Boehringer) for 30 min at
4° C. Nuclei and insoluble debris were removed by centrifugation
at 14 000 rpm for 30 min. Aliquots of 1–5 × 106 cell equivalents of
a cleared lysate were mixed with Laemmli buffer, boiled for 5 min,
separated on 10% polyacrylamide SDS-gels, and then transfer-
red onto Immobilon PVDF membranes (Millipore, Eschborn,
Germany). Membranes were blocked overnight in blocking
reagent (Boehringer). Antibody binding was detected by incuba-
tion with horseradish peroxidase-conjugated goat anti-rabbit
immunoglobulin (Dianova) followed by enhanced chemilumines-
cence using Super-Signal-Ultra (Pierce, Rockford IL, USA).
Flow cytometry
Cells (5 × 105 per sample) were washed in PBS supplemented with
1% BSA (PBS/BSA) and incubated on ice with FITC- or PE-
conjugated or unlabelled primary mAb for 30 min. After washing
in PBS/BSA, cells were either fixed in 1% formaldehyde for flow
cytometry, or, for unlabelled primary mAb, a secondary staining
reagent, FITC-goat anti-hamster IgG (FITC-GAH) or FITC-goat
anti-mouse IgG (FITC-GAM) or FITC-rabbit anti-rat IgG (FITC-
RAR) or FITC-goat anti-rabbit IgG (FITC-GAR) was applied for
30 min at 4° C. Background fluorescence was evaluated using
either FITC-or PE-coupled irrelevant matched isotypes, or unla-
belled matched isotypes and FITC-GAH, FITC-GAM, FITC-RAR
or FITC-GAR. Cell surface fluorescent labelling was visualized
on an EPICS®-PROFILE II flow cytometer (Coulter Immunotec
Co, Hamburg, Germany) and data analysis was performed using
EPICS®ELITE 3.0 software.
Antigen presentation assay
Presentation assays were performed by incubating A20 B cells or
IFN-γ -stimulated (150 U ml–1 for 48 h) P388D1 macrophages 
as APCs (5 × 104 cells per well), T cells specific for OVA323–339
presented by H2-Ad or T cells specific for HA111–119 presented by
H2-Ed (both at 2 × 105 cells per well), and varying concentrations
of antigen in flat-bottomed 96-well plates in a final volume of 
200 µ l per well. Supernatants were collected after 24 h and
assayed for IFN-γ by ELISA as recently described (Lingnau et al,
1998). Alternatively, A20 and P388D1 cells were fixed in 1%
paraformaldehyde at room temperature for 20 min and washed
extensively with CM prior to assay.
RESULTS
Differential expression of MHC class II and CIITA in 
IL-4, IL-10 or IFN-γ -stimulated tumour cell lines
In order to examine the regulation of genes involved in the MHC
class II antigen processing and presentation pathway, we defined
the status of MHC class II cell surface (H2-A and H2-E) and
CIITA mRNA expression in a panel of murine tumour cell lines
prior to and after stimulation with IL-4, IL-10 or IFN-γ . Table 1
summarizes the mean values of fluorescence obtained for H2-A
and H2-E expression correlated with specific CIITA transcripts in
IL-4, IL-10 or IFN-γ -treated cells. Tumour cell lines could be
divided into three groups based on MHC class II cell surface
expression. The first group is defined by constitutive MHC class II
and CIITA expression and includes the B cell lymphoma cell lines
A20 and LB27.4, as well as the macrophage cell line P388D1.
Different cytokines were found to enhance H2-A and H2-E cell-
surface expression dependent on the cell type: IL-4 represents the
most potent stimulus for the B-cell lymphoma cell lines and IFN-γ
for P388D1 macrophages. Remarkably, stimulation of P388D1
cells with IL-10 did not affect steady state H2-A surface expres-
sion level, but resulted in a reduced number of detectable H2-E
surface molecules as compared to P388D1 cells cultured in
medium without cytokine addition. The second group exhibits no
constitutive, but inducible expression of MHC class II and CIITA
genes upon IFN-γ -treatment, represented by the macrophage-
derived cell line APC IC-21, the melanoma cell line B16, L929
fibroblasts and the renal adenocarcinoma cell line Renca. Of note,
although IFN-γ -treatment of Renca cells did not induce appre-
ciable H2-A or H2-E surface expression, RT-PCR analysis of H2-
Aa, -Ab, -Ea and -Eb mRNA expression demonstrated the
presence of specific mRNA for all components of the MHC class
II antigen presentation pathway in concert with CIITA mRNA after
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passes cell lines that lack both constitutive and IFN-γ -inducible
MHC class II or CIITA expression including the mammary adeno-
carcinoma TS/A, the colon adenocarcinoma MC-38, the hepatic
fibrosarcoma MCA-102, the mastocytoma P815 and the T cell-
derived cell lines RMA, RMAs, EL-4 and YAC-1.
Discoordinate vs coordinate expression of H2-M and
MHC class II genes in tumour cells
To address the question whether H2-M and MHC class II genes
are coordinately regulated in IL-4, IL-10 or IFN-γ -stimulated
tumour cells, we analysed Ma and Mb mRNA expression by RT-
PCR. Low levels of Ma and Mb mRNA could be detected in each
cell line independent of MHC class II and CIITA expression (data
not shown). In view of this and based on the observation that the
human  DMA and  DMB genes appear to be co-regulated
(Westerheide et al, 1997), we examined the regulation of H2-M
genes by analysing Ma mRNA expression in untreated, IL-4-, IL-
10- or IFN-γ -stimulated tumour cells utilizing a semiquantitative
RT-PCR approach. In a first step, the amount of cDNA of each
individual sample was evaluated using β -actin as a standard
(Figure 1A–C), followed by determination of the Ma mRNA
expression level (Figure 1D–F). For both steps, constant amounts
of cDNA and serially diluted competitor fragments were co-
amplified (Figure 1A and 1D). The concentration of the
competitor required to achieve equal band intensities for both
fragments was determined by linear regression analysis (Figure
1B and 1E) and the relative mRNA levels (molecules µ g–1 of total
RNA) were calculated (Figure 1C and 1F, white bars). In order to
determine differences in Ma mRNA expression levels, the relative
amount of β -actin mRNA molecules was used to standardize the
cDNA contents of each sample (Figure 1F, black bars). The
results of the competitive RT-PCR analysis for each cell line are
summarized in Table 2. Coordinate regulation of MHC class II
and H2-M genes could be detected in the CIITA-positive B cell
lines A20 and LB27.4. Like MHC class II, IL-4 followed by IFN-
γ and IL-10 represented the most potent upregulator of constitu-
tive Ma mRNA expression (Figure 1F and Table 2). Similar to its
effect on MHC class II, IFN-γ induced a substantial increase of
basal  Ma mRNA expression in CIITA-positive tumour cells,
including P388D1 and IC-21 macrophages, L929 fibroblasts, B16
(melanoma) and Renca (renal adenocarcinoma) cells. Enhanced
Ma mRNA expression could also be detected in IL-4-treated
P388D1 and IC21 macrophages, while IL-4 did not impact on Ma
mRNA levels in IL-4-stimulated L929, B16 and Renca tumour
cells, which lack CIITA and MHC class II. Stimulation of
P388D1, IC21, B16, L929 and Renca cells with IL-10 did not
result in significant increase or decrease of Ma mRNA expression
as compared to untreated control cells. Most interestingly, neither
IL-4, IL-10 nor IFN-γ was able to modulate Ma mRNA expres-
sion in CIITA- and MHC class II-negative cell lines including the
mammary adenocarcinoma TS/A, the colon adenocarcinoma MC-
38, the hepatic fibrosarcoma MCA-102 and the T cell-derived cell
lines RMA, RMAs, EL-4 and YAC-1. However, both IL-4 and IL-
10 markedly induced Ma mRNA levels in P815 mastocytoma
cells which lack detectable MHC class II and CIITA mRNA
expression (Table 2).
Taken together, these results indicate that H2-M, independent of
CIITA, is constitutively expressed and that CIITA appears to be
required for coordinate regulation of H2-M and MHC class II
expression by cytokines that control Th1 or Th2 immune responses.
Mb1 and Mb2 are differentially expressed in IL-4-, IL-10-
or IFN-γ -stimulated tumour cells
We investigated whether Mb1 and  Mb2 genes are differentially
expressed in IL-4, IL-10 or IFN-γ -treated cells by ratio RT-PCR
analysis. Discrimination between co-amplified Mb1 and  Mb2
isoforms was performed by restriction enzyme analysis using
specific restriction sites for each Mb type in the amplified DNA (see
Materials and Methods section). In summary, a divergent expression
pattern of both Mb genes could be observed (Table 3). Mb2 was
predominantly expressed in the transformed B cell lines A20 and
LB27.4. As shown in Figure 2A, the majority of the Mbd amplicons
from untreated, IL-4-, IL-10- or IFN-γ -stimulated A20 B cells was
cleaved by the Mb2d-specific restriction endonuclease XbaI (Figure
2A, lane X). This result is confirmed by complementary digestion
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Table 1 Expression of cell surface MHC class II Ags and CIITA mRNA in cytokine-treated professional and nonprofessional APCs
H2-A surface expression H2-E surface expression CIITA mRNA expression
Cell-line Histology Nil IL-4 IL-10 IFN-γ Nil IL-4 IL-10 IFN-γ Nil IL-4 IL-10 IFN-γ
A20 B cell lymphoma 25.54 57.61 41.28 31.73 99.75 165.41 161.71 128.68 + + + +
LB27.4 B cell lymphoma 16.31 24.18 19.1 21.45 26.77 45.32 39.58 42.89 + + + +
P388D1 macrophage 1.34 3.78 1.36 14.42 3.76 11.67 2.72 51.93 + + + +
IC-21 macrophage 0.59 0.74 0.56 2.62 n.d. n.d. n.d. n.d. ––– +
B16 melanoma 0.23 0.51 0.97 8.57 n.d. n.d. n.d. n.d. ––– +
L929 fibroblast 0.61 0.65 0.58 2.89 n.d. n.d. n.d. n.d. ––– +
Renca renal cell adenocarcinoma 0.60 0.73 0.89 0.75 0.82 0.91 0.78 0.87 ––– +
P815 mastocytoma 0.88 0.96 0.77 0.72 0.87 0.92 0.83 0.74 ––– –
TS/A mamma adenocarcinoma 0.22 0.29 0.23 0.26 0.47 0.51 0.55 0.49 ––– –
MC-38 colon adenocarcinoma 0.45 0.42 0.57 0.59 n.d. n.d. n.d. n.d. ––– –
MCA-102 fibroblast 0.34 0.29 0.39 0.37 n.d. n.d. n.d. n.d. ––– –
EL-4 thymoma 0.12 0.07 0.08 0.10 n.d. n.d. n.d. n.d. ––– –
RMA T cell lymphoma 0.32 0.39 0.47 0.44 n.d. n.d. n.d. n.d. ––– –
RMAs T cell lymphoma 0.46 0.40 0.53 0.41 n.d. n.d. n.d. n.d. ––– –
YAC-1 T cell lymphoma 0.17 0.19 0.19 0.20 n.d. n.d. n.d. n.d. ––– –
Cells were stained with FITC-or PE-conjugated isotype-matched irrelevant antibody (negative control), FITC-labelled mAb 39-10-8 (anti-H2-Ad), or PE-
conjugated mAb 14-4-4S (anti-H2-Ek,d) and analysed by flow cytometry. Results are expressed as mean channel fluorescence. Expression of CIITA mRNA was
determined by RT-PCR as described in Material and Methods. Cells were cultured in medium (Nil) or in medium supplemented with 250 U ml–1 IL-4, 100 ng ml–1
IL-10 or 150 U ml–1 IFN-γ for 48 h.with EaeI, that specifically cleaves Mb1d (Figure 2A, lane E). As an
additional control, complete cleavage was obtained by a combina-
tion of XbaI and EaeI (Figure 2A, lane E and X), demonstrating that
the Mb1 and Mb2 expression pattern was not due to heterodimer
formation, which may occur between closely related sequences
during RT-PCR (Becker Andre and Hahlbrock, 1989). In compar-
ison, both Mb genes were found to be expressed in the P815 masto-
cytoma cell line (Table 3). However, stimulation of P815 cells with
IL-10 augmented Mb2 expression, while IL-4 or IFN-γ did not exert
any effect on the Mb1 or Mb2 mRNA expression pattern.
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Figure 1 Competitive RT-PCR analysis of β -actin and H2-Ma mRNA expression in IL-4, IL-10 or IFN-γ -stimulated A20 B cells. A20 cells were cultured in
medium alone (Nil) or medium supplemented with 250 U ml–1 IL-4, 100 ng ml–1 IL-10 or 150 U ml–1 IFN-γ for 48 h prior to RNA isolation and cDNA synthesis. Left
panel, evaluation of β -actin mRNA concentration in each cDNA sample. (A) PCR reactions were performed by titrating 4-fold serial dilutions of the β -actin
competitor plasmid, starting with 4.8 × 109 molecules (in lanes 1, 7, 11 and 16) with a constant amount of cDNA (50 ng). After 30 amplification cycles, PCR
products were resolved on a 1.7% agarose/EtBr gel and intensity of each band corresponding to the cellular β -actin amplicon (wt) and β -actin competitor
fragment (cf) was quantified as OD302 units by densitometric imaging. (B) The log of the ratios of the two types of products were graphed as a function of the
initial amount of competitor plasmid added to the PCR reactions. The initial amount of cellular β -actin mRNA in each reaction was determined by linear
regression analysis and extrapolated from the point of the graph where the ratio of the two types of products is equimolar (log wt/cf = 0). (C) The specific β -actin
mRNA levels for each sample expressed as mRNA molecules µ g–1 total cellular RNA. Right panel, estimation of Ma mRNA expression in IL-4, IL-10 or IFN-γ -
treated A20 cells. (D–E) the same experiment as for the quantification of β -actin mRNA was performed, except that 100 ng cDNA of each sample and a 2-fold
serial diluted Ma competitor fragment was used, starting with 5.86 × 105 molecules (for Nil and IL-10, lanes 1 and 11), 2.34 × 106 molecules (for IL-4, lane 6) and
1.17 × 106 molecules (for IFN-γ , lane 16). (F) The level of Ma mRNA expression in each sample was plotted as Ma mRNA molecules µ g–1 total cellular RNA
before (open bars) and after normalization of their cDNA contents using β -actin mRNA expression as a standard (filled bars)In contrast, Mb1 was the prominent transcript in P388D1
macrophages and in tumour cells of epithelial origin including the
renal adenocarcinoma Renca and the mammary adenocarcinoma
TS/A. IFN-γ -treatment of P388D1, Renca and TSA cells enhanced
Mb1 expression as compared to untreated, IL-4- or IL-10-stimulated
cells. Moreover, Mb1 was found to be exclusively expressed in IC-
21 macrophages, L929 fibroblasts, the hepatic fibrosarcoma MCA
102, the colon adenocarcinoma MC-38 and the B16 melanoma, as
well as in the T cell-derived cell lines RMA, RMAs, EL-4 and YAC-
1 (Table 3). As shown in Figure 2B, BamHI digestion of Mbb ampli-
cons from IL-4-, IL-10- or IFN-γ -treated B16 and L929 cells yielded
restriction fragments exclusively corresponding to Mb1b transcripts,
while fragments corresponding to Mb2b could not be detected as
compared to the C57/BL (H2b) spleen control. The complete
cleavage of the Mbb amplification product by BamHI confirmed that
heterodimer formation did not occur during RT-PCR amplification.
Mαβ 1 and Mαβ 2 heterodimers are expressed in tumour
cells
Next, we addressed the question whether differential expression of
Ma, Mb1 and Mb2 genes is restricted to mRNA expression, or
whether Mαβ 1 and Mαβ 1 heterodimers exist in tumour cells of
different histology. Western immunoblots of lysates from
untreated, IL-4-, IL-10- or IFN-γ -stimulated A20 B cells, P388D1
macrophages, B16 melanoma and EL-4 thymoma cells were
stained with a polyclonal rabbit serum raised against the cyto-
plasmic domain of Mα or an antiserum which recognizes both Mβ
isoforms in order to assess H2-M protein expression (Figure 3). As
expected (see Table 2), A20, P388D1, B16 and EL-4 cells did
express detectable amounts of Mα monomers (Figure 3, left
panel). Modulation of Mα monomer expression by IL-4, IL-10 or
IFN-γ correlated with Ma mRNA expression levels in cytokine-
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Table 2 Regulation of Ma mRNA expression in professional and nonprofessional APCs by IL-4 IL-10 and IFN-γ
Cells Nil IL-4 IL-10 IFNγ
A20 1.0 (1.2 × 106) 4.1 (4.9 × 106) 1.7 (2.0 × 106) 2.7 (3.2 × 106)
LB27.4 1.0 (1.6 × 106) 6.1 (9.8 × 106) 1.5 (2.4 × 106) 2.9 (4.6 × 106)
P388D1 1.0 (2.2 × 105) 2.7 (5.9 × 105) 0.9 (1.9 × 105) 5.9 (1.3 × 106)
IC-21 1.0 (8.1 × 104) 3.5 (2.8 × 105) 0.9 (7.3 × 104) 11.2 (9.1 × 105)
B16 1.0 (2.4 × 104) 1.1 (2.7 × 104) 1.0 (2.4 × 104) 10.4 (2.5 × 105)
L929 1.0 (5.1 × 104) 1.4 (7.3 × 104) 1.2 (6.3 × 104) 6.5 (3.3 × 105)
Renca 1.0 (4.3 × 104) 1.1 (4.6 × 104) 1.1 (4.7 × 104) 3.0 (1.3 × 105)
P815 1.0 (8.5 × 104) 3.0 (2.6 × 105) 3.8 (3.2 × 105) 1.3 (1.1 × 105)
TS/A 1.0 (8.6 × 103) 1.0 (8.8 × 103) 1.4 (1.2 × 104) 1.3 (1.1 × 104)
MC-38 1.0 (2.5 × 104) 1.0 (2.4 × 104) 1.4 (3.5 × 104) 1.0 (2.6 × 104)
MCA-102 1.0 (1.3 × 104) 1.2 (1.5 × 104) 1.0 (1.2 × 104) 1.2 (1.6 × 104)
EL-4 1.0 (3.9 × 103) 1.2 (4.6 × 103) 0.9 (3.6 × 103) 1.0 (4.0 × 103)
RMAs 1.0 (1.1 × 104) 0.9 (9.8 × 103) 0.9 (1.0 × 104) 1.1 (1.2 × 104)
RMA 1.0 (4.3 × 104) 1.3 (5.5 × 104) 1.0 (4.4 × 104) 1.1 (4.8 × 104)
YAC-1 1.0 (3.6 × 104) 1.3 (4.7 × 104) 1.1 (4.0 × 104) 0.9 (3.2 × 104)
Cells were cultured in medium (Nil) or medium supplemented with 250 U ml–1 IL-4, 100 ng ml–1 IL-10 or 
150 U ml–1 IFN-γ for 48 h prior to RNA isolation and cDNA synthesis. Expression of Ma mRNA was determined
by competitive RT-PCR. β -actin mRNA expression was used to normalize each individual sample. Relative Ma
mRNA expression in cytokine-treated samples of each cell line is expressed as the ratio: Ma mRNA in cytokine
treated cells / Mα mRNA expression (ratio = 1.0) in untreated cells. The number of Ma mRNA molecules µ g–1
total RNA for each sample are shown in brackets.
Table 3 Differential expression of Mb1 and Mb2 mRNA in IL-4, IL-10 or IFNγ -treated professional and nonprofessional APCs
Nil IL-4 IL-10 IFNγ
Cells Mb1 Mb2 Mb1 Mb2 Mb1 Mb2 Mb1 Mb2
A20 4.3 ± 0.5 95.7 ± 0.4 5.9 ± 1.3 94.1 ± 0.9 14.6 ± 2.0 85.4 ± 1.7 6.7 ± 1.1 93.3 ± 0.7
LB27.4 16.8 ± 2.5 83.2 ± 4.2 15.9 ± 1.6 84.1 ± 2.0 27.7 ± 2.4 72.3 ± 3.9 15.3 ± 1.7 84.7 ± 3.1
P815 43.6 ± 1.7 56.4 ± 2.4 39.3 ± 2.1 60.7 ± 2.0 28.6 ± 2.8 71.4 ± 2.3 44.1 ± 1.1 55.9 ± 1.7
P388D1 88.7 ± 0.3 11.3 ± 0.7 83.8 ± 1.3 16.2 ± 2.4 89.2 ± 1.2 10.8 ± 0.9 93.6 ± 0.2 6.4 ± 0.6
TS/A 64.5 ± 1.3 35.5 ± 1.4 63.6 ± 2.0 36.4 ± 1.5 67.8 ± 2.8 32.2 ± 1.8 97.3 ± 0.9 2.7 ± 0.6
Renca 82.7 ± 2.5 17.3 ± 4.2 84.8 ± 3.9 15.2 ± 4.5 88.4 ± 1.7 11.6 ± 2.5 91.2 ± 3.6 8.8 ± 2.4
MC-38 100 0 100 0 100 0 100 0
IC-21 100 0 100 0 100 0 100 0
B16 100 0 100 0 100 0 100 0
L929 100 0 100 0 100 0 100 0
MCA-102 100 0 100 0 100 0 100 0
EL-4 100 0 100 0 100 0 100 0
RMA 100 0 100 0 100 0 100 0
RMAs 100 0 100 0 100 0 100 0
YAC-1 100 0 100 0 100 0 100 0
Expression of Mb1 and Mb2 mRNA was assayed by ratio-RT-PCR analysis. Cells were cultured in medium (Nil) or medium supplemented with 250 U ml–1 IL-4,
100 ng ml–1 IL-10 or 150 U ml–1 IFN-γ for 48 h prior to assay. Values indicate the relative expression levels of alternative Mb isoforms as a percentage of total Mb
mRNA expression. Values are means ± SD for three determinations.stimulated A20, P388D1, B16 and EL-4 cells (Table 2), suggesting
that expression of H2-M gene expression is primarily regulated at
the transcriptional level. Noteworthy, untreated, IL-4-, IL-10- or
IFN-γ -stimulated P388D1, B16 and EL-4 cells expressed Mβ 1
monomers, while A20 cells expressed Mβ 2 (Table 3 and Figure 3,
right panel). Comparison of Mα and Mβ expression in untreated,
IL-4-, IL-10- or IFN-γ -stimulated A20, P388D1, B16 and EL-4
cells revealed a similar pattern, implicating that expression of Ma
and Mb genes might be co-regulated similarly to human DMA and
DMB (Peleraux et al, 1996).
Alternative H2-M isoforms display similar functional
activities in antigen presentation to H2-Ad- and 
H2-Ed-restricted CD4+ T cells
To assess whether differential expression of H2-M isoforms
impacts on the presentation of native protein antigens, we studied
the ability of Mαβ 1-expressing P388D1 macrophages and Mαβ 2-
expressing A20 B cells to effectively process and present surro-
gate target antigens, ovalbumin (OVA) and influenza
haemagglutinin (HA) and the corresponding peptides to H2-Ad-
and H2-Ed-restricted CD4 + T cells from TCR transgenic mice. To
ensure that levels of H2-M and MHC class II expressed in P388D1
macrophages were comparable to those in A20 B cells (Tables 1
and 2), P388D1 cells were stimulated with IFN-γ for 48 h prior to
antigen presentation. As shown in Figure 4, P388D1 (Mαβ 1) as
well as A20 (Mαβ 2) cells were able to process and present native
OVA and HA to H2-Ad- and H2-Ed-restricted CD4+ T cells,
respectively. In contrast, presentation of native antigens by fixed
APCs was severely impaired, indicating that the capacity of
P388D1 and A20 cells to process and present the OVA323–339 and
HA107–122 determinants did not result from extracellular antigen
processing or peptide contamination. As expected, native and
paraformaldehyde-fixed P388D1 and A20 cells present exoge-
nously supplied OVA323–339 or HA107–122 peptides to CD4+ T cell
populations. Overall, these findings implicate equivalent func-
tional capabilities for individual H2-M isoforms in selecting the
OVA323–339 or HA107–122 T cell epitopes presented by H2-Ad and H2-
Ed, respectively.
DISCUSSION
H2-M is a MHC class II-like heterodimeric molecule which
appears to be required for efficient antigen presentation by many
MHC class II alleles (Denzin et al, 1994; Miyazaki et al, 1996;
Wolf et al, 1998). The rationale of this work was twofold, first to
investigate whether H2-M and MHC class II genes are coordi-
nately regulated by cytokines in tumour cells, and second, whether
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Figure 3 H2-M protein expression is differentially regulated in A20 B cells,
P388D1 macrophages, B16 melanoma cells and EL-4 thymoma cells by IL-4,
IL-10 or IFN-γ . Whole cell lysates were separated using a denaturing SDS-
PAGE (12.5%) and analysed by a Western immunoblot by staining with the
rabbit antiserum R.Mα -C.69.3 (anti-Mα ) or Mβ 1/2-C.71.3 (anti-Mβ 1 and 
-Mβ 2). The arrowheads show the position of the ~ 27 kD Mβ monomers
according to the predicted MW (Cho et al, 1991). Where indicated, cells were
cultured in medium (Nil) or in medium supplemented with 250 U ml–1 IL-4,
100 ng ml–1 IL-10 or 150 U ml–1 IFN-γ for 48 h before preparation of the cell
lysatesthe two Mb genes of the H2-M region are differentially expressed
and display similar or distinct functional activities in MHC class II
antigen presentation.
The present study demonstrates that H2-M and MHC class II
gene expression is coordinately regulated by IL-4, IL-10 or IFN-γ
in transformed cells derived from professional APCs (i.e.
macrophages or B cells) in the presence of CIITA. This is in agree-
ment with previous data which indicated that the 5′ proximal
promoter region of H2-M and MHC class II genes share conserved
cis-acting sequences (Peleraux et al, 1996), particularly the ‘X1
box’, which binds the RFX transcription factor complex that
appears to be crucial for CIITA interaction (Scholl et al, 1997).
In contrast, our analysis identified low levels of H2-M tran-
scripts in nonprofessional APCs prior to IFN-γ -mediated induc-
tion of CIITA expression (Table 2), implicating that basal H2-M
expression might occur independently of CIITA. Indeed, CIITA-
deficient mice still exhibit a basal level of Mb expression in
splenocytes (Chang et al, 1996), and some IFN-γ -responsive
human cell lines express detectable amounts of DM transcripts in
the absence of CIITA expression (Westerheide et al, 1997; Sartoris
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(Mαβ 1) or A20 cells (Mαβ 2) as APCs in the presence of increasing antigen concentrations or synthetic peptides. Supernatants were collected after 24 h and
tested for IFN-γ secretion. APCs were fixed with 1% paraformaldehyde prior to assay1200 W Walter et al
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et al, 1998). Furthermore, our data demonstrate that murine
tumour cell lines which are deficient in IFN-γ -mediated CIITA
expression, such as MCA-102, TS/A, or MC-38 (Tables 1 and 2),
do not exhibit increased basal H2-M expression levels, nor induc-
tion of MHC class II gene expression following IFN-γ -treatment.
Taken together, these observations can be reconciled with a model
in which CIITA is a prerequisite in professional and nonprofes-
sional APCs for co-regulation of genes which are instrumental for
efficient MHC class II antigen presentation. However, based on
data presented in this report, CIITA might be no longer viewed as
the exclusive regulator for H2-M expression.
Additionally, suppression of CIITA activity, in addition to the
occurrence of tumour antigen loss variants (Kerkmann-Tucek et al,
1998), may provide one potential mechanism for neoplastic cells
to escape immune surveillance. Notably not only the lack of
inducible CIITA expression (e.g. tumour cells summarized in
Table 1), may account for insufficient MHC class II cell surface
expression. Other, as yet poorly defined, factors may be respon-
sible for the failure of tumour cells to upregulate MHC class II. For
instance, IFNγ -treatment of the renal cell carcinoma Renca results
in CIITA mRNA expression (Table 1), enhanced H2-Ma mRNA
expression, but does not lead to H2-A, or H2-E cell surface expres-
sion (Table 1).
H2-Ma, -Mb1 and -Mb2 are co-expressed in splenocytes of mice
carrying different haplotypes (Walter et al, 1996), indicating that
Mαβ 1 and Mαβ 2 heterodimers might be operational in antigen
presentation by many MHC class II alleles/isotypes. As shown 
in this study, Mb1 is predominantly expressed in transformed
macrophages, melanoma cells and in tumour cells of epithelial and
mesenchymal origin, while Mb2 is expressed in B cells. Of note,
the mastocytoma cell line P815 was found to express both Mb
genes at almost equal levels (Table 3). Differential expression of
members of a gene family in different cell types or at different
developmental stages has been described for many eukaryotic
genes (Hardison, 1998). For instance, an inverse relationship
between gene activity and levels of CpG dinucleotide methylation
has been observed (Hsieh, 1997; Agarwal and Rao, 1998). The 5′
flanking promoter region of both Mb genes contains conserved S,
X1, X2 and Y elements (Peleraux et al, 1996) which is required for
constitutive and inducible expression (Mach et al, 1996). Since
DNA methylation has been proposed to affect chromatin structure
(Hsieh, 1997), methylation of CpG islands may critically influence
the binding of transcription factors to cis-acting sequences and
which may be able to silence the transcriptional activity of the
Mb2 promoter in a cell-type-specific manner. Alternatively, but
not mutually exclusive, cellular diversity of Mb1 and Mb2 expres-
sion might be controlled by cell-type-specific transcriptional
activators selectively interacting with one of the Mb promoters.
Alternative CIITA isoforms have been discovered, which selec-
tively control cell-type-specific and inducible MHC class II
expression (Muhlethaler Mottet et al, 1997).
Mb1 and  Mb2 differ predominantly within exon 2, where
similarity at the nucleotide level drops to 90%, as compared to
97–100% within the other exons (Walter et al, 1996). The present
study addressed the question whether H2-M isoforms differ within
their functional capabilities in MHC class II antigen presentation.
P388D1 and A20 cells, which selectively express Mαβ 1 and
Mαβ 2, respectively, can process and present the OVA323–339 and
HA107–122 epitopes to H2-Ad- and H2-Ed-restricted CD4 + T cells,
implicating a similar biological activity of both H2-M isoforms in
mice carrying two functional MHC class II isotypes. Consistent
with these observations, recent crystallographic analysis revealed
a comparable overall molecular surface architecture of both H2-M
isoforms, suggesting similar functional activities in peptide
loading (Fremont et al, 1998).
The apparent lack or need of certain human or murine MHC
class II alleles to require DM/H2-M for CLIP removal in vivo
(Denzin et al, 1994; Miyazaki et al, 1996; Wolf et al, 1998) has
been attributed to the affinities of these MHC class II alleles for
CLIP as determined by in vitro binding studies (Sette et al, 1995).
Moreover, the apparent lack of Ii or H2-M in tumour cells in the
presence of MHC class II cell surface expression may turn out to
be beneficial for the host. Tumour cells transfected with syngeneic
MHC class II genes without co-expressing Ii or Ii/H2M are highly
immunogenic and appear to present rather endogenous as
compared to exogenous antigens to tumour-specific T cells
(Armstrong et al, 1997).
In summary, Th1- and Th2-associated cytokines coordinately
regulate expression of genes involved in the MHC class II antigen
processing and presentation pathway in the presence of CIITA in a
cell-type-specific manner. Yet, our findings established for the first
time that Mαβ 1 and Mαβ 2 are selectively expressed in different
murine tumour cells and that both isoforms can select for MHC
class II/peptide assembly. Future studies may address whether
differences in the MHC class II antigen presentation pathway in
tumour cells impacts on disease progression and clinical outcome
of vaccine strategies targeting tumour-associated antigens
displayed by MHC class II molecules.
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